CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 93 enrolled
Drug / intervention
AR-13324 Ophthalmic Solution 0.02% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02246764
NCT02246764Phase 3Completed
CompareCT.gov

A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety of AR-13324 Ophthalmic Solution, 0.02% QD & BID Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure

Aerie Pharmaceuticals·interventional·Posted Sep 23, 2014·Updated Apr 6, 2018

In Brief

A Phase 3 clinical trial evaluating AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, and 2 other interventions for Ocular Hypertension and Glaucoma. Completed, enrolled 93 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Glaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 23, 2014
Enrollment StartSep 1, 2014
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.8 years ago

Interventions

AR-13324 Ophthalmic Solution 0.02%drug

1 drop once daily (QD), PM, OU

AR-13324 Ophthalmic Solution 0.02% BIDdrug

1 drop BID, AM/PM, OU

Timolol maleate Ophthalmic Solution 0.5% BIDdrug

1 drop BID, AM/PM, OU

Placeboother

1 drop QD, AM, OU